Increasing Global Prevalence of Alzheimer’s and Improvising Regulatory Scenario Drives the Global Alzheimer’s Drugs Market

Alzheimer’s disease is a neurodegenerative disorder that causes slow decline in abilities such as thinking, reasoning, and routine daily activities, alongside memory loss. This may lead to planning or solving problems, poor judgment, lack of social activities, and personality and mood changes, which are considered the most common symptoms of Alzheimer’s disease. Symptoms of Alzheimer’s disease generally begin to appear in patients in their mid-sixties. As per World Alzheimer’s report, one new case of AD is registered every 3.2 seconds. The death burden from Alzheimer’s disease is increasing in all developed and growing countries in recent years following growth of the geriatric demographic. There is no cure for Alzheimer’s yet but a number of marketed drug help improve symptoms. There is no modified disease drug in the market, resulting in high unmet need for the Alzheimer’s drug market.

Obtain Report Details @ http://www.transparencymarketresearch.com/alzheimers-drugs-market.html

North America Dominates Global Alzheimer’s Market due to Widespread Awareness

The global Alzheimer’s drug market is segmented on the basis of drug class type, distribution channel, and region. Based on drug class, the Alzheimer’s drug market has been segmented into cholinergic, memantine, combined drugs, others. Memantine dominated the global Alzheimer’s drugs market in 2016 due to patent expiry of major products and the limited number of Alzheimer’s drugs. The memantine segment is expected to remain dominant through the forecast period. The cholinergic segment is expected to have a considerable share in the global Alzheimer’s drugs market and is likely to expand at a strong CAGR during the forecast period due to the limited availability of effective drug classes globally. Combined drug class sales increased in 2016 compared to previous years, and this segment is anticipated to expand at a significant CAGR during forecast periods.

The global Alzheimer’s drugs market is segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy, and online sales. The hospital pharmacy segment has held the largest share in the Alzheimer’s drug market in 2016 due to the growing demand for Alzheimer’s treatment in hospitals. The hospital pharmacy segment is projected to expand at a significant CAGR during forecast period. The online sales segment is expected to gain a stronger market share during the forecast period, due to the growing use of mobile-based applications for ordering the medicines.

On the basis of geography, the global Alzheimer’s drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held the largest share in the global Alzheimer’s drugs market in 2016 due to the high number of Alzheimer’s patients and the growing awareness about the disease in the region. The North America Alzheimer’s drugs market was valued at US$1.7 bn in 2017 and is likely to rise to more than US$3 bn by 2025. The Asia Pacific market, meanwhile, is likely to exhibit a robust 8.6% CAGR between 2017 and 2025. Latin America and the Middle East and Africa are relatively smaller markets for Alzheimer’s drugs. However, the Brazil Alzheimer’s drugs market is expected to grow at a significant CAGR in forecast period and the country is likely to dominate the Alzheimer’s drugs market in Latin America.

Make an Enquiry @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1245

Limited Number of Branded Drugs Holding Alzheimer’s Market Back

The key market drivers for global Alzheimer’s market are the increasing prevalence of the disease. Increasing awareness has played a key role in the growth of the global Alzheimer’s drug market, but in several developing regions the treatment facilities remain behind the time due to the high prices of advanced drugs. High pricing and lack of limited branded drugs are thus the key restraints for the Alzheimer’s drug market. Success in developing effective drugs at low costs is thus the major research strategy of players in the Alzheimer’s drugs market.

Allergan plc and Novartis AG dominated the global Alzheimer’s drugs market in 2016. Their global market presence and acquisition of leading brands have contributed to their dominance. Other key players in the global Alzheimer’s drugs market include Eisai Co Ltd, H Lundbeck A/S, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co Ltd, Merz Holding GmbH & Co KG, and Johnson & Johnson.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.